PRESS ROOM

PSYCHECEUTICAL IN THE PRESS

New Clinical Trial is Testing a Ketamine Skin Cream for PTSD

Read Feature

Psycheceutical Starts a Phase I Trial With Topical Ketamine

Read Feature

NeuroDirect™ Ketamine: Novel, Non-Systemic Topical Therapy for PTSD & Associated Intractable Depression

Read Feature

Top Biotech Startup 2023 – Psycheceutical: Leveraging the Therapeutic Power of Psychedelics

Read Feature

Psycheceutical’s Topical PTSD Drug Poised for Human Trials

Read Feature

Psycheceutical Developing The First Ever Topical Psychedelic Cream To Treat PTSD

Read Feature

Psycheceutical Listed as 1 of 7 Psychedelic Stocks to Watch

Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical

Read Feature

Kevin Harrington Becomes The Latest ‘Shark Tank’ Judge To Enter The Psychedelics Space

Read Feature

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Read Feature

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

Read Feature

Armed With Two Patents, Psycheceutical Plans To Transform Psychedelic Drug Delivery

Read Feature

Psycheceutical Licenses New Delivery Technologies For Psychedelic Medicines

Read Feature

Biotech Company Earns Two Patents for Targeted Delivery of Psychedelic Medicines

Read Story

Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption

Read Story

Psychedelic Business Spotlight: Psycheceutical, Inc., Announces Exclusive License of Two Major Patents

Read Story

PODCASTS

Chad Harman, CEO of Psycheceutical, Sits in the Psychedelic Invest Investor Hotseat

Psycheceutical: Frontiers of Treatment with Dr. Thomas Cabell and Chad Harman

Psycheceutical’s Zappy Zapolin On The Psychedelic Invest Podcast

Psycheceutical CEO, Chad Harman, On The Street Smart Podcast

PRESS RELEASES

08/10/2023 in Press Releases

Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD

Company's novel NeuroDirectTM topical ketamine formulation to treat PTSD shown to be safe and well-tolerated in first cohort of Phase I trial.

08/01/2023 in Press Releases

Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy

Psycheceutical today announced that its auditors RBSM LLP have completed a PCAOB audit of the company's financial statements for the periods ending December 31, 2022 and 2021.

07/13/2023 in Press Releases

First Patient Dosed in Psycheceutical’s Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD

Psycheceutical’s clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder through the company’s NeuroDirect™ delivery system.

06/01/2023 in Press Releases

Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD

Company raises $1.3M USD convertible note from Cantheon Capital for in-human trials of patented novel ketamine cream.

04/13/2023 in Press Releases

Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review

MIAMI — April 13, 2023 —Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health…

03/29/2023 in Press Releases

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab

Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD...

03/21/2023 in Press Releases

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD

A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical cream Patients indicated their thought processes…

02/15/2023 in Press Releases

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in Australia

02/02/2023 in Press Releases

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD

01/26/2023 in Press Releases

Psycheceutical Bioscience Files Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD)

01/10/2023 in Press Releases

Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer

Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics

11/29/2022 in Press Releases

Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director

Dr. Logsdon’s expertise to help guide the company’s further research and development for its patented drug-delivery technology.

10/18/2022 in Press Releases

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments...

10/04/2022 in Press Releases

Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board.

08/16/2022 in Press Releases

Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences

Vici Health Sciences CEO Anish Dhanarajan to join Psycheceutical as Research and Development Advisor.

05/10/2022 in Press Releases

Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor

Famed entrepreneur excited about the company’s development of psychedelic pharmaceutical medicines to treat the widespread mental health crisis.

03/29/2022 in Press Releases

Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis

Psycheceutical Chief Visionary Officer, Zappy Zapolin, will be a featured presenter at the esteemed Legacy Investment Summit 2022, to be held at the Mandarin Oriental Hotel in Washington, D.C. on March 31…

03/15/2022 in Press Releases

Psycheceutical Announces Agreement with Vici Health Sciences

Psycheceutical, Inc. has announced it has entered into a strategic agreement with Vici Health Sciences, known for providing pharmaceutical clients with tools to innovate and grow through new product development.…

03/01/2022 in Press Releases

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Esteemed neurosurgeon to participate in strategy, direction for development of novel psychedelic therapy innovations.

01/20/2022 in Press Releases

Psycheceutical Completes Acquisition by Blue Water Ventures International

Psycheceutical, Inc., today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).

For interviews, media kits or other public relations inquiries, please contact:

press@psycheceutical.com

Contact

OTC: BWVI

PRESS ROOM

PSYCHECEUTICAL IN THE PRESS

PODCASTS

Chad Harman, CEO of Psycheceutical, Sits in the Psychedelic Invest Investor Hotseat

Psycheceutical: Frontiers of Treatment with Dr. Thomas Cabell and Chad Harman

Psycheceutical’s Zappy Zapolin On The Psychedelic Invest Podcast

Psycheceutical CEO, Chad Harman, On The Street Smart Podcast

PRESS RELEASES

Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD

Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy

First Patient Dosed in Psycheceutical’s Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD

Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD

Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

Psycheceutical Bioscience Files Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer

Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences

Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor

Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis

Psycheceutical Announces Agreement with Vici Health Sciences

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Psycheceutical Completes Acquisition by Blue Water Ventures International

MEDIA CONTACT

For interviews, media kits or other public relations inquiries, please contact:

press@psycheceutical.com

Psycheceutical Bioscience, Inc. (OTC: BWVI) is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines.

OTC: BWVI

PRESS ROOM

PSYCHECEUTICAL IN THE PRESS

PODCASTS

Chad Harman, CEO of Psycheceutical, Sits in the Psychedelic Invest Investor Hotseat

Psycheceutical: Frontiers of Treatment with Dr. Thomas Cabell and Chad Harman

Psycheceutical’s Zappy Zapolin On The Psychedelic Invest Podcast

Psycheceutical CEO, Chad Harman, On The Street Smart Podcast

PRESS RELEASES

Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD

Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy

First Patient Dosed in Psycheceutical’s Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD

Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD

Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

Psycheceutical Bioscience Files Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer

Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences

Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor

Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis

Psycheceutical Announces Agreement with Vici Health Sciences

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Psycheceutical Completes Acquisition by Blue Water Ventures International

MEDIA CONTACT

For interviews, media kits or other public relations inquiries, please contact:

press@psycheceutical.com

SUBSCRIBE FOR EMAIL UPDATES:

Psycheceutical Bioscience, Inc. (OTC: BWVI) is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines.

GET EMAIL UPDATES FROM PSYCHECEUTICAL, INC.